Non-surgical treatment for eyelid retraction in thyroid eye disease (TED)

被引:19
作者
Grisolia, Ana Beatriz Diniz [1 ]
Couso, Ricardo Christopher [2 ]
Matayoshi, Suzana [3 ]
Douglas, Raymond S. [4 ]
Briceno, Cesar Augusto [2 ]
机构
[1] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol, Sch Med, Ann Arbor, MI 48105 USA
[2] Univ Penn, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Sao Paulo, Med Sch, Div Ophthalmol, Sao Paulo, Brazil
[4] Cedars Sinai Med Ctr, Orbital & Thyroid Eye Dis Program, Los Angeles, CA 90048 USA
关键词
HYALURONIC-ACID GEL; UPPER-LID RETRACTION; TOXIN TYPE-A; GRAVES OPHTHALMOPATHY; SUBCONJUNCTIVAL INJECTION; TRIAMCINOLONE INJECTION; NATURAL-HISTORY; ORBITOPATHY; MANAGEMENT; LAGOPHTHALMOS;
D O I
10.1136/bjophthalmol-2017-310695
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Thyroid eye disease (TED) is an autoimmune condition with an unpredictable course that may lead to permanent facial disfigurement. Eyelid retraction is one of the most common findings, and frequently demands attention due to ocular exposure and impaired cosmesis. Surgical treatment remains the most effective option, but there is a role for temporary corrections during the active phase of the disease, as well as in patients who are poor surgical candidates. The aim of this review is to describe the non-surgical modalities currently available for treatment of eyelid malposition in TED. The authors have focused on the use of hyaluronic acid, triamcinolone injections and botulinum toxin type A as non-surgical treatment alternatives, paying special attention to dosing, technique, efficacy and duration of effect. Non-surgical treatment modalities may represent viable in cases where surgical correction is not an option. Although temporary, these modalities appear to be beneficial for ocular exposure remediation, improving quality of life and broadening our therapeutic arsenal.
引用
收藏
页码:158 / 163
页数:6
相关论文
共 65 条
[1]   The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy [J].
Bartalena, Luigi ;
Baldeschi, Lelio ;
Boboridis, Kostas ;
Eckstein, Anja ;
Kahaly, George J. ;
Marcocci, Claudio ;
Perros, Petros ;
Salvi, Mario ;
Wiersinga, Wilmar M. .
EUROPEAN THYROID JOURNAL, 2016, 5 (01) :9-26
[2]   Extrathyroidal manifestations of Graves' disease: a 2014 update [J].
Bartalena, Luigi ;
Fatourechi, Vahab .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2014, 37 (08) :691-700
[3]   Rundle and His Curve [J].
Bartley, George B. .
ARCHIVES OF OPHTHALMOLOGY, 2011, 129 (03) :356-358
[4]  
BIGLAN AW, 1994, OPHTHALMIC SURG LAS, V25, P186
[5]  
Briceno Cesar A, 2013, Int Ophthalmol Clin, V53, P93, DOI 10.1097/IIO.0b013e318293c44e
[6]   LEVATOR RECESSION - WITH REATTACHMENT TO TARSUS WITH COLLAGEN FILM [J].
CALLAHAN, A .
ARCHIVES OF OPHTHALMOLOGY, 1965, 73 (06) :800-&
[7]   Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series [J].
Chee, E. ;
Chee, S-P .
EYE, 2008, 22 (02) :311-315
[8]   Comparative study of Botox® injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage [J].
Costa, P. G. ;
Saraiva, F. P. ;
Pereira, I. C. ;
Monteiro, M. L. R. ;
Matayoshi, S. .
EYE, 2009, 23 (04) :767-773
[9]   Evaluating Graves' Orbitopathy [J].
Dolman, Peter J. .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 26 (03) :229-248
[10]   Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone [J].
Ebner, R ;
Devoto, MH ;
Weil, D ;
Bordaberry, M ;
Mir, C ;
Martinez, H ;
Bonelli, L ;
Niepomniszcze, H .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (11) :1380-1386